AQR Capital Management
PDSB icon

AQR Capital Management’s PDS Biotechnology PDSB Stock Holding History

AQR Capital Management’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-22,156
Closed -$64.9K – 2851
2024
Q2 		$64.9K Buy
22,156
+1,300
+6% +$4.16K ﹤0.01% 2529
2024
Q1 		$82.6K Sell
20,856
-8,409
-29% -$43.3K ﹤0.01% 2356
2023
Q4 		$145K Buy
29,265
+6,838
+30% +$34K ﹤0.01% 2252
2023
Q3 		$113K Buy
+22,427
New +$123K ﹤0.01% 2215

Other funds holding PDSB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

AQR Capital Management's PDSB Position: Q3 2024 in Review

AQR Capital Management sold out of PDS Biotechnology (PDSB) in Q3 2024, closing a stake of 22,156 shares — an estimated $64.9K sold.

AQR Capital Management first reported a position in PDSB in Q3 2023 and held it in 4 quarters. The position peaked at $145K in Q4 2023. 57 funds tracked by Wall St. Rank hold PDSB as of Q3 2024.

  • AQR Capital Management reported no remaining PDS Biotechnology position as of Q3 2024 after selling out during the quarter.
  • AQR Capital Management sold 22,156 PDS Biotechnology shares in Q3 2024, an estimated $64.9K.
  • AQR Capital Management first reported a position in PDS Biotechnology in Q3 2023 and held it in 4 quarters.
  • AQR Capital Management's PDS Biotechnology position peaked at $145K in Q4 2023.
  • 57 funds tracked by Wall St. Rank held PDS Biotechnology as of Q3 2024.

Based on AQR Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.